Company news
Bcal Diagnostics Limited (ASX:BDX) news
Every Bcal Diagnostics Limited press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
BCAL Secures Funding for FY2027 Update
August 21, 2026
BCAL to Acquire Shares in Genetic Signatures
July 1, 2026
BCAL Secures Funding for FY2027
June 28, 2026
BCAL Develops New Blood Test for Breast Cancer Recurrence
June 17, 2026
BCAL Launches Early Detection Cancer Platform
May 19, 2026
BCAL Appoints Anne-Louise Arnett as Chief Executive Officer
May 10, 2026
BCAL Accelerates Rollout of Avantect Early Detection Tests
March 25, 2026
Half Yearly Report and Accounts
February 17, 2026
Shareholder Update
February 4, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 20, 2026
BCAL Early Cancer Detection Tests Update
November 18, 2025
BCAL Establishes $10m Convertible Note Facility Revised
October 19, 2025
BCAL Establishes $10 million Convertible Note Facility
October 19, 2025
BCAL and ClearNote Partner on Early Cancer Detection Tests
September 18, 2025
Appendix 4E and Annual Report
August 29, 2025
BCAL Partners with Sonic Healthcare
August 26, 2025
Commercial Partnership with Cancer Care Associates
July 2, 2025
Investor Presentation
March 24, 2025
BCAL Launches Breastest Plus Generating First Revenues
March 23, 2025
NATA Accreditation Clarification
December 12, 2024
BCAL Diagnostics Receives NATA Accreditation
December 11, 2024
Appendix 4E and Annual Report to Shareholders
August 30, 2024
BCAL Commences US Operations
August 28, 2024
BCAL Receives Firm Commitments to Raise $10.5 Million
June 3, 2024
Reinstatement to Quotation
June 3, 2024
Suspension from Quotation
May 30, 2024
Response to ASX Price Query
May 30, 2024
Trading Halt
May 29, 2024
Pause in Trading
May 29, 2024
Appointment of Strategic CEO to Lead Commercial Launch
March 5, 2024
Share Purchase Plan Offer Booklet
August 29, 2023
Preliminary Final Report
August 29, 2023
$2.4m Capital Raise to Further BREASTEST Commercialisation
August 27, 2023
Breakthrough Results a Major Step Towards Commercialisation
August 1, 2023
BCAL Enters US Product Development Agreement with Precion
June 28, 2022
Appendix 4D & Interim Report
February 17, 2022
7 February Announcement - Additional Information
February 8, 2022
Recent Analysis Significantly Improves Commercial Prospects
February 6, 2022
Dr John Hurrell Appointed Chief Executive Officer
January 10, 2022
Strong Cohort 4 Testing Data Demonstrates Value of BCAL Test
November 2, 2021
Australian Clinical Studies Launched
September 3, 2021
Market Update
August 17, 2021